Posted by: fuadelhibri on: February 1, 2011
ROCKVILLE, Md., Jan 25, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is being developed in collaboration with [...]
Posted by: fuadelhibri on: January 7, 2011
By Marjorie Censer Monday, January 3, 2011 Fuad El-Hibri has lived in all sorts of exotic locales, working for Citicorp in Saudi Arabia, consulting for Booz Allen Hamilton in Indonesia and establishing mobile telecommunications businesses in Russia, Venezuela and El Salvador. But getting started in his current position as chief executive of Rockville-based pharmaceutical company [...]
Posted by: fuadelhibri on: June 7, 2010
Fuad El-Hibri, CEO of Emergent BioSolutions Inc., announces that the company will be participating in the following investor conferences during June 2010: The Jefferies & Company 2010 Global Life Sciences Conference New York, NY. June 8, 2010 Corporate Overview Presentation 11:00 AM Eastern There will be a full webcast with slides that will include discussion [...]
